ReportSYSTEMIC AMYLOIDOSIS

Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis

See allHide authors and affiliations

Science Translational Medicine  03 Jan 2018:
Vol. 10, Issue 422, eaan3128
DOI: 10.1126/scitranslmed.aan3128

Article Information

vol. 10 no. 422

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication March 27, 2017
  • Accepted for publication September 26, 2017

Author Information

  1. Duncan B. Richards1,
  2. Louise M. Cookson1,
  3. Sharon V. Barton1,
  4. Lia Liefaard1,
  5. Thirusha Lane2,
  6. David F. Hutt2,
  7. James M. Ritter3,
  8. Marianna Fontana2,
  9. James C. Moon4,
  10. Julian D. Gillmore2,
  11. Ashutosh Wechalekar2,
  12. Philip N. Hawkins2 and
  13. Mark B. Pepys2,5,*
  1. 1GlaxoSmithKline Research and Development, Stevenage, Herts SG1 2NY, UK.
  2. 2National Health Service National Amyloidosis Centre, Centre for Amyloidosis and Acute Phase Proteins, University College London and Royal Free Hospital, London NW3 2PF, UK.
  3. 3Quintiles Drug Research Unit, Guy’s Hospital, London SE1 1YR, UK.
  4. 4University College London Institute of Cardiovascular Science and Barts Heart Centre, St Bartholomew’s Hospital, London EC1A 7BE, UK.
  5. 5Wolfson Drug Discovery Unit, Centre for Amyloidosis and Acute Phase Proteins, University College London, London NW3 2PF, UK.
  1. *Corresponding author. Email: m.pepys{at}ucl.ac.uk

Altmetric

Article usage

Article usage: December 2017 to December 2018

AbstractFullPdf
Dec 2017322
Jan 20184736162353
Feb 201835746113
Mar 20182373173
Apr 20183133471
May 20182541346
Jun 20182251323
Jul 20182072330
Aug 20181353539
Sep 20181784029
Oct 20181764332
Nov 20181883729
Dec 20186294